Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012 (2012), Article ID 607498, 12 pages
Research Article

Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model in the Mongolian Gerbil

1National Center for Laboratory Animal Breeding, Havana, Cuba
2Histology Department, Preclinical and Basic Science Institute, Havana, Cuba
3Center of Molecular Immunology (CIM), Havana, Cuba
4Center of Research and Development of Medicaments (CIDEM), Havana, Cuba
5Institute of Neurology and Neurosurgery (INN), Havana, Cuba

Received 18 June 2011; Accepted 24 January 2012

Academic Editor: Dirk M. Hermann

Copyright © 2012 Iliana Sosa Teste et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cerebrovascular disease is the third leading cause of death and the leading cause of disability in Cuba and in several developed countries. A possible neuroprotective agent is the rHu-EPO, whose effects have been demonstrated in models of brain ischemia. The Neuro-EPO is a derivative of the rHu-EPO that avoids the stimulation of erythropoiesis. The aim of this study was to determine the Neuro-EPO delivery into the central nervous system (CNS) to exert a neuroprotective effect in cerebral ischemia model of the Mongolian gerbil. The Neuro-EPO in a rate of 249.4 UI every 8 hours for 4 days showed 25% higher viability efficacy ( 𝑃 > 0 . 0 1 ), improving neurological score and behavior of the spontaneous exploratory activity, the preservation of CA3 areas of the hippocampus, the cortex, and thalamic nuclei in the focal ischemia model of the Mongolian gerbil. In summary, this study, the average dose-used Neuro-EPO (249.4 UI/10 μL/every 8 hours for 4 days), proved to be valid indicators of viability, neurological status, and spontaneous exploratory activity, being significantly lower than that reported for the systemically use of the rHu-EPO as a neuroprotectant. Indeed, up to 12 h after brain ischemia is very positive Neuro-EPO administration by the nasal route as a candidate for neuroprotection.